Celltrion Inc
- Country
- π§πͺBelgium
- Ownership
- -
- Established
- 1999-01-01
- Employees
- -
- Market Cap
- $31.9B
- Website
- http://www.celltrion.com/
To Compare Efficacy and Safety of CT-P39 and EU-approved Xolair in Patients With Chronic Spontaneous Urticaria
- Conditions
- Interventions
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 634
- Registration Number
- NCT04426890
- Locations
- π΅π±
Klinika Ambroziak ESTEDERM, Warszawa, Poland
Study to Compare PK and Safety of Subcutaneous Injection of Ustekinumab and CT-P43 in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2021-08-05
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 271
- Registration Number
- NCT04428814
- Locations
- π³πΏ
Auckland Clinical Studies Limited, Grafton, Auckland, New Zealand
π³πΏChristchurch Clinical Studies Trust Limited, Christchurch, Canterbury, New Zealand
A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 in Subjects With Obstructive Hypertrophic Cardiomyopathy
- Conditions
- Interventions
- First Posted Date
- 2020-06-05
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 23
- Registration Number
- NCT04418297
- Locations
- πΊπΈ
Cedars-Sinai Medical Center, Los Angeles, California, United States
πΊπΈTufts Medical Center, Boston, Massachusetts, United States
π΅π±Institute of Cardiology in Warsaw, Warsaw, Mazowieckie, Poland
To Compare the Pharmacokinetics and Safety of the Auto-injector and Pre-filled Syringe of CT-P17
- First Posted Date
- 2020-03-04
- Last Posted Date
- 2021-01-19
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 180
- Registration Number
- NCT04295356
- Locations
- πΊπΈ
PPD Development, LP, Austin, Texas, United States
CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Ulcerative Colitis (LIBERTY-UC)
- Conditions
- Interventions
- First Posted Date
- 2019-12-19
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 548
- Registration Number
- NCT04205643
- Locations
- π΅π±
Centrum Zdrowia MDM, Warszawa, Poland
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
- First Posted Date
- 2019-11-20
- Last Posted Date
- 2021-11-17
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 62
- Registration Number
- NCT04171414
- Locations
- π΅π±
Nasz Lekarz Osrodek Badan Klinicznych, Bydgoszcz, Poland
To Compare the PK and Safety of Omalizumab (CT-P39, EU-approved Xolair, and US-licensed Xolair) in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2019-07-12
- Last Posted Date
- 2023-05-11
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 176
- Registration Number
- NCT04018313
- Locations
- π¦πΊ
Phase 1 unit, Adelaide, South Australia, Australia
To Compare the Pharmacokinetics and Safety of CT-P17 and Humira in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2019-06-03
- Last Posted Date
- 2021-11-18
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 312
- Registration Number
- NCT03970824
- Locations
- π°π·
Chonbuk National University Hospital, Jeonju, Jeollabuk-do, Korea, Republic of
π°π·Chungbuk National University Hospital, Cheongju-si, Chungcheongbuk-do, Korea, Republic of
π°π·Severance Hospital, Seoul, Korea, Republic of
CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn's Disease (LIBERTY-CD)
- Conditions
- Interventions
- First Posted Date
- 2019-05-10
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 396
- Registration Number
- NCT03945019
- Locations
- πΊπΈ
Biopharma Informatic - Houston, Houston, Texas, United States
π¨πΏFakultni nemocnice Ostrava, Ostrava, Czechia
π«π·Centre Hospitalier Lyon Sud, Pierre-BΓ©nite, France
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 or CT-G11 and Food Effect of CT-G20 in Human Participants
- Conditions
- Interventions
- First Posted Date
- 2019-04-18
- Last Posted Date
- 2020-06-09
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 72
- Registration Number
- NCT03918967
- Locations
- π°π·
Seoul National University Hospital, Seoul, Korea, Republic of